Summary

Induced Pluripotent Stem Cells Market – Scope of Report
TMR’s report on the global induced pluripotent stem cells market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global induced pluripotent stem cells market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global induced pluripotent stem cells market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the induced pluripotent stem cells market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global induced pluripotent stem cells market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global induced pluripotent stem cells market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global induced pluripotent stem cells market.

The report delves into the competitive landscape of the global induced pluripotent stem cells market. Key players operating in the global induced pluripotent stem cells market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global induced pluripotent stem cells market profiled in this report.

Key Questions Answered in Global induced pluripotent stem cells Market Report
• What is the sales/revenue generated by induced pluripotent stem cells across all regions during the forecast period?
• What are the opportunities in the global induced pluripotent stem cells market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Induced Pluripotent Stem Cells Market – Research Objectives and Research Approach
The comprehensive report on the global induced pluripotent stem cells market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global induced pluripotent stem cells market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global induced pluripotent stem cells market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Induced Pluripotent Stem Cells Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Induced Pluripotent Stem Cells Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Induced Pluripotent Stem Cells Market Analysis and Forecast, by Cell Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Cell Type, 2020-2034
6.3.1. Hepatocytes
6.3.2. Fibroblasts
6.3.3. Keratinocytes
6.3.4. Others (Neurons, etc.)
6.4. Market Attractiveness Analysis, by Cell Type
7. Global Induced Pluripotent Stem Cells Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2020-2034
7.3.1. Drug Development
7.3.2. Regenerative Medicine
7.3.3. Toxicity Testing
7.3.4. Tissue Engineering
7.3.5. Cell Therapy
7.3.6. Disease Modeling
7.4. Market Attractiveness Analysis, by Application
8. Global Induced Pluripotent Stem Cells Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Hospitals
8.3.2. Diagnostic Centers
8.3.3. Pharmaceutical & Biotechnology Companies
8.3.4. Contract Research Organizations
8.3.5. Others (Academic & Research Institutes, etc.)
8.4. Market Attractiveness Analysis, by End-user
9. Global Induced Pluripotent Stem Cells Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Induced Pluripotent Stem Cells Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Cell Type, 2020-2034
10.3.1. Hepatocytes
10.3.2. Fibroblasts
10.3.3. Keratinocytes
10.3.4. Others (Neurons, etc.)
10.4. Market Value Forecast, by Application, 2020-2034
10.4.1. Drug Development
10.4.2. Regenerative Medicine
10.4.3. Toxicity Testing
10.4.4. Tissue Engineering
10.4.5. Cell Therapy
10.4.6. Disease Modeling
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Hospitals
10.5.2. Diagnostic Centers
10.5.3. Pharmaceutical & Biotechnology Companies
10.5.4. Contract Research Organizations
10.5.5. Others (Academic & Research Institutes, etc.)
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Cell Type
10.7.2. By Application
10.7.3. By End-user
10.7.4. By Country
11. Europe Induced Pluripotent Stem Cells Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Cell Type, 2020-2034
11.3.1. Hepatocytes
11.3.2. Fibroblasts
11.3.3. Keratinocytes
11.3.4. Others (Neurons, etc.)
11.4. Market Value Forecast, by Application, 2020-2034
11.4.1. Drug Development
11.4.2. Regenerative Medicine
11.4.3. Toxicity Testing
11.4.4. Tissue Engineering
11.4.5. Cell Therapy
11.4.6. Disease Modeling
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Hospitals
11.5.2. Diagnostic Centers
11.5.3. Pharmaceutical & Biotechnology Companies
11.5.4. Contract Research Organizations
11.5.5. Others (Academic & Research Institutes, etc.)
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Cell Type
11.7.2. By Application
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Induced Pluripotent Stem Cells Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Cell Type, 2020-2034
12.3.1. Hepatocytes
12.3.2. Fibroblasts
12.3.3. Keratinocytes
12.3.4. Others (Neurons, etc.)
12.4. Market Value Forecast, by Application, 2020-2034
12.4.1. Drug Development
12.4.2. Regenerative Medicine
12.4.3. Toxicity Testing
12.4.4. Tissue Engineering
12.4.5. Cell Therapy
12.4.6. Disease Modeling
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Hospitals
12.5.2. Diagnostic Centers
12.5.3. Pharmaceutical & Biotechnology Companies
12.5.4. Contract Research Organizations
12.5.5. Others (Academic & Research Institutes, etc.)
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Cell Type
12.7.2. By Application
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Induced Pluripotent Stem Cells Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Cell Type, 2020-2034
13.3.1. Hepatocytes
13.3.2. Fibroblasts
13.3.3. Keratinocytes
13.3.4. Others (Neurons, etc.)
13.4. Market Value Forecast, by Application, 2020-2034
13.4.1. Drug Development
13.4.2. Regenerative Medicine
13.4.3. Toxicity Testing
13.4.4. Tissue Engineering
13.4.5. Cell Therapy
13.4.6. Disease Modeling
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Hospitals
13.5.2. Diagnostic Centers
13.5.3. Pharmaceutical & Biotechnology Companies
13.5.4. Contract Research Organizations
13.5.5. Others (Academic & Research Institutes, etc.)
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Cell Type
13.7.2. By Application
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Induced Pluripotent Stem Cells Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Cell Type, 2020-2034
14.3.1. Hepatocytes
14.3.2. Fibroblasts
14.3.3. Keratinocytes
14.3.4. Others (Neurons, etc.)
14.4. Market Value Forecast, by Application, 2020-2034
14.4.1. Drug Development
14.4.2. Regenerative Medicine
14.4.3. Toxicity Testing
14.4.4. Tissue Engineering
14.4.5. Cell Therapy
14.4.6. Disease Modeling
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Hospitals
14.5.2. Diagnostic Centers
14.5.3. Pharmaceutical & Biotechnology Companies
14.5.4. Contract Research Organizations
14.5.5. Others (Academic & Research Institutes, etc.)
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Cell Type
14.7.2. By Application
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Axol Bioscience
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Cynata Therapeutics Limited
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Evotec SE
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Fate Therapeutics
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. FUJIFILM Cellular Dynamics, Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Ncardia
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. LizarBio Therapeutics
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. REPROCELL Global
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Sumitomo Dainippon Pharma Company Limited
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Takara Bio USA, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Thermo Fisher Scientific
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Vertex Pharmaceuticals
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview